01762nas a2200373   4500000000100000008004100001260001300042653001500055653001000070653000900080653001800089653001000107653001100117653001100128653002100139653002100160653001800181653001200199653002600211653001600237653001600253653000900269653001600278653002400294653001800318100001600336700001300352700001300365245013200378300001000510490000700520520084700527022001401374       1987                            d  c1987 Jun10aAdolescent10aAdult10aAged10aCell Division10aChild10aFemale10aHumans10aImmune Tolerance10aImmunoglobulin G10aInterleukin-210aleprosy10aLymphocyte Activation10aLymphocytes10aLymphokines10aMale10aMiddle Aged10aPhytohemagglutinins10aT-Lymphocytes1 aHussein Y M1 aKerr M A1 aBeck J S00aThe mechanism of action of the factor in leprosy serum that inhibits the growth of mitogen-stimulated normal human lymphocytes.  a125-90 v613 a<p>A factor found in the serum of patients with leprosy that inhibits the growth of mitogen-stimulated normal peripheral blood lymphocytes has been studied. The inhibitor, previously identified as an IgG, has been shown to act by blocking the recruitment of lymphocytes into growth. It was not cytotoxic and did not inhibit the rate of growth of those lymphocytes that had been stimulated. The inhibitory activity was less potent if the serum was added after mitogen stimulation. The inhibitor, which could be absorbed by activated but not resting lymphocyte cultures, appeared to act by inhibition of an early event preceding the release of IL-2. The inhibition of mitogen stimulation was overcome by the addition of purified IL-2, although the inhibitor did not block the action of IL-2 on a long-term cultured IL-2-dependent cell line.</p>  a0019-2805